## 2 Material and Methods
### Antibacterial Activity  
The antibacterial activity was studied according to the effect of the essential oils against Gram-negative and Gram-positive bacteria (Table 2) by determining the diameters of inhibition using the agar well diffusion test [26]. This method is widely used for the evaluation of the antibacterial activity of essential oils. In this manipulation, the surfaces of the petri dishes were inoculated by spreading 100 \(\upmu\)L of the bacterial suspension over the entire surface of the Mueller-Hinton Medium agar. Then, four perforations were made (diameter: 6 mm; depth: 5 mm), one for the negative control (dimethylsulfoxide DMSO 5%), one for the positive control (commercial antibiotics + DMSO 5%), one for CSEO and the last for NAEO. It is noted that the two essential oils were tested at a concentration of 5% in DMSO, and three repetitions were made per test and for each strain. The antibacterial activity was evaluated according to the zone of inhibition visualized after incubation of the petri dishes for 24 h at 37 \({}^{\circ}\)C.  
\begin{table}
\begin{tabular}{c c c c} \hline \hline
**Cell Lines** & **Origin** & **Source** & **Growth Medium** \\ \hline A2780 & _Ovarian carcinoma_ & ECACC-93112517 & Gibco RPMI 1640 \\ \hline A549 & _Lung carcinoma_ & ATCC\({}^{\otimes}\)-CCL-18 STM & Gibco RPMI 1640 \\ \hline HCT116 & _Colorectal carcinoma_ & ATCC\({}^{\otimes}\)-CCL-247 TM & Gibco McCoy’s 5A \\ \hline HEK-293 & _Embryonic kidney_ & ATCC\({}^{\otimes}\)-CRL-1573 TM & Gibco RPMI 1640 \\ \hline JIMT-T1 & _Breast carcinoma_ & DSMZ-ACC 589 & Gibco DMEM \\ \hline K562 & _Myelogenous leukemia_ & ATCC\({}^{\otimes}\)-CCL-243 TM & Gibco RPMI 1640 \\ \hline MIA-Paca2 & _Pancreas carcinoma_ & ATCC\({}^{\otimes}\)-CRL-1420 TM & Gibco DMEM \\ \hline MRC5 & _Lung normal_ & ATCC\({}^{\otimes}\)-CCL-171 TM & Gibco DMEM \\ \hline NCI-N87 & _Gastric carcinoma_ & ATCC\({}^{\otimes}\)-CRL-5822 TM & Gibco RPMI 1640 \\ \hline PC3 & _Prostate carcinoma_ & ATCC\({}^{\otimes}\)-CRL-1435 TM & Gibco RPMI 1640 \\ \hline RT4 & _Urinary bladder_ & ATCC\({}^{\otimes}\)-HTB-2 TM & Gibco McCoy’s 5A \\ \hline U2 OS & _Bone osteosarcoma_ & ATCC\({}^{\otimes}\)-HTB-96 TM & Gibco McCoy’s 5A \\ \hline U87-MG & _Brain glioblastoma_ & ATCC\({}^{\otimes}\)-HTB-14 TM & Gibco DMEM \\ \hline \hline \end{tabular}
\end{table}
Table 1: The origin, source and growth medium of 13 cancer cell lines used in the cytotoxicity test.  
\begin{table}
\begin{tabular}{c c c} \hline \hline
**Gram Negative** & \multicolumn{2}{c}{**Gram Positive**} \\ \hline
**Strains** & **Code/Source** & **Strains** & **Code/Source** \\ \hline _Acineobacter baumannii_ & ATCC 19606 & \\ _Enterobacter cloace_ & Clinical isolate & _Corynebacterium_ sp. & Clinical isolate \\ _Escherichia coli_ & ATCC 25922 & _Enterococcus faecalis_ & ATCC 29212 \\ _Klebsiella pneumoniae_ & ATCC 700603 & _Staphylococcus aureus_ & ATCC 29213 \\ _Pseudomonas aeruginosa_ & ATCC 27853 & _Staphylococcus epidermidis_ & Clinical isolate \\ _Salmonella enterica_ & ATCC 13311 & _Streptococcus agalacticiae_ & ATCC 27956 \\ _Shigella somaei_ & _ATCC 9290_ & \\ \hline \hline \end{tabular}
\end{table}
Table 2: The strains used during the antibacterial test.